Attovia Therapeutics (NASDAQ:ATTO) Coverage Initiated at Citigroup

Equities researchers at Citigroup assumed coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a report issued on Monday. The brokerage set a “buy” rating and a $30.00 price target on the stock. Citigroup’s price target would indicate a potential upside of 44.93% from the company’s current price.

Several other equities analysts have also issued reports on the company. Leerink Partners began coverage on Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $52.00 price target on the stock. Morgan Stanley assumed coverage on shares of Attovia Therapeutics in a research report on Monday. They set an “overweight” rating and a $39.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Attovia Therapeutics presently has an average rating of “Buy” and a consensus price target of $41.50.

Attovia Therapeutics Stock Performance

Shares of Attovia Therapeutics stock opened at $20.70 on Monday. Attovia Therapeutics has a one year low of $16.15 and a one year high of $24.32.

Insider Buying and Selling

In other news, major shareholder Redmile Group, Llc purchased 200,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $3,400,000.00. Following the purchase, the insider owned 982,854 shares in the company, valued at $16,708,518. This represents a 25.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio purchased 382,352 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,499,984.00. Following the acquisition, the insider owned 4,181,367 shares of the company’s stock, valued at approximately $71,083,239. This represents a 10.06% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 2,740,587 shares of company stock worth $47,269,979 over the last 90 days.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its holdings in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.